## FORM 51-102F3 MATERIAL CHANGE REPORT

## Item 1. Name and Address of Company

State the full name of your company and the address of its principal office in Canada:

Enertopia Corp. (the "Company") 950 - 1130 West Pender Street Vancouver, BC V6E 4A4

### Item 2. Date of Material Change

September 17, 2014

## Item 3. News Release

The Company did disseminate a news release through Newswire.ca on September 17, 2014. The Company announced the material change by filing a Form 8-K with the Securities and Exchange Commission on September 17, 2014.

## Item 4. Summary of Material Change

On September 17, 2014, the Company announced a corporate update on the Burlingotn Joint Venture.

### **Full Description of Material Change**

See attached Form 8-K.

### Item 5. Reliance on subsection 7.1(2) or (3) of National Instrument 51-102

If this report is being filed on a confidential basis in reliance of subsection 7.1(2) or (3) of National Instrument 51-102, state the reasons for such reliance.

Not Applicable.

### Item 6. Omitted Information

Not Applicable.

#### Item 7. <u>Executive Officer</u>

Give the name and business telephone number of an executive officer of your company who is knowledgeable about the material change and the Report, or the name of an officer through whom such executive officer may be contacted.

Please contact Robert McAllister, CEO and President of the Company, at 604.602.1675

# Item 8. <u>Date of Report</u>

DATED September 17, 2014.

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

## FORM 8-K

Current Report
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (date of earliest event 1	reported): September 17, 2	2014
ENERTOPIA CORP.  (Exact name of registrant as specified in its charter)		
(State or other jurisdiction	(Commission	(IRS Employer
of incorporation)	File Number)	Identification No.)
#950 – 1130 West Pender Stre (Address of pr Registrant's telephone number, including a	incipal executive offices) (Zip co	
(Former name of	or former address, if changed sin	ce last report.)
Check the appropriate box below if the Forthe registrant under any of the following property of	•	iltaneously satisfy the filing obligation of
<ul> <li>Written communications pursuant to R</li> <li>Soliciting material pursuant to Rule 14</li> <li>Pre-commencement communications p</li> <li>Pre-commencement communications p</li> </ul>	a-12 under the Exchange Act (1 pursuant to Rule 14d-2(b) under	7 CFR 240.14a-12) the Exchange Act (17 CFR 240.14d-2(b))

## Item 7.01 Regulation FD Disclosure.

On September 17, 2014, the Company announced a corporate update on the Burlington Joint Venture.

A copy of the news release is filed as exhibit 99.1 to this current report and is hereby incorporated by reference.

### ITEM 9.01. FINANCIAL STATEMENTS AND EXHIBITS.

(d) Exhibits.

Exhibit No.

**Description** 

99.1 Press Release dated September 17, 2014

### **SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: September 17, 2014

Enertopia Corp.

By: <u>"Robert McAllister"</u>

Robert G. McAllister

President and Director



Press Release #201439

FOR IMMEDIATE RELEASE

**September 17, 2014** 

# **Enertopia Provides Burlington Lexaria JV Update**

**VANCOUVER, BC** – **September 17, 2014 - Enertopia Corporation** (ENRT-OTCBB) (TOP-CSE) (the "Company" or "Enertopia") announces the Burlington, Ontario Application is in the Health Canada Preliminary Screening process.

The company is pleased to advise shareholders that its Joint Venture partner, Lexaria Corp (LXRP), and the Company have submitted their application for Licensed Producer in July 2014 and are in regular correspondence with Health Canada with respect to specific aspects of the licensing process, which are being handled by Ontario Operations Manager Mr. Donald Shaxon as responsible person in charge.

The Burlington Joint Venture with Lexaria Corp has applied to produce 10,000kg of Medical Marihuana per year under its Licensed Producer application. Enertopia has 51% interest in the joint venture and Lexaria Corp 49% as disclosed on April 9, 2014 in Enertopia's press release #201424.

The Burlington JV has requested a Ready to build letter from Health Canada once the application has been accepted from Health Canada, see step 5 below.

For those not familiar with the Health Canada process for becoming a licensed producer, below are the levels to be reached through the application process. Note there are no specific process times for each step, however one could progress from preliminary screening to ready to build letter in as little as 90 to 120 days depending on the application submitted to Health Canada:

Step 1: Preliminary Screening Step 2: Enhanced Screening

Step 3: Security Clearance

Step 4: Review

Step 5: Ready to build letter (if required by applicant)

Step 6: Pre-licence inspection

Step 7: Licensing

The Joint Venture (JV) has been active in the local community and has received very good community and media support. The JV also met with the local policing authority and upon licensing by Health Canada we have proposed that the local police could conduct security and swat team training at the facility. We are very pleased to be working closely with law enforcement and look forward to their insights in preventative and proactive security measures.

Enertopia at this time publically acknowledges its support for the Lexaria Corp policy on the responsible use of medical marijuana announced on August 28, 2014. Therefore, Enertopia is establishing a corporate policy wherein we will not knowingly sell medical cannabis containing more than 0.3% THC to any medical marijuana patient who is under the age of 21, unless it is in a form specifically approved by relevant government health agencies.

"Enertopia's overriding responsibility is to cause no harm and keep Medical Marijuana as a safe and secure option for patients in search of natural healing options." Stated President / CEO Robert McAllister.

# **About Enertopia**

Enertopia's shares are quoted in Canada with symbol TOP and in the United States with symbol ENRT. For additional information, please visit www.enertopia.com or call Ken Faulkner, Business and Institutional Development: (250) 765-3630 Clark Kent, Media Inquiries: (647) 519-2646

This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Statements which are not historical facts are forward-looking statements. The Company makes forward-looking public statements concerning its expected future financial position, results of operations, cash flows, financing plans, business strategy, products and services, potential licensing and financing of its medical marihuana projects, evaluation of clean energy projects, oil & gas projects, , competitive positions, growth opportunities, plans and objectives of management for future operations, including statements that include words such as "anticipate," "if," "believe," "plan," "estimate," "expect," "intend," "may," "could," "should," "will," and other similar expressions that are forward-looking statements. Such forward-looking statements are estimates reflecting the Company's best judgment based upon current information and involve a number of risks and uncertainties, and there can be no assurance that other factors will not affect the accuracy of such forward-looking statements., foreign exchange and other financial markets; changes of the interest rates on borrowings; hedging activities; changes in commodity prices; changes in the investments and exploration expenditure levels; litigation; legislation; environmental, judicial, regulatory, political and competitive developments in areas in which Enertopia Corporation operates. The User should refer to the risk disclosures set out in the periodic reports and other disclosure documents filed by Enertopia Corporation from time to time with regulatory authorities. There is no assurance that the Burlington Joint Venture will obtain a license under MMPR and or that the Company will be able to obtain future financings.

The CSE has not reviewed and does not accept responsibility for the adequacy or accuracy of this release